Kornimate/medical-research-clean huggingface dataset:
efficacy of exercise, manual therapy and tele-rehabilitation-assisted treatment on degenerative cervical diseases

Conditions: Cervical Spine Disease; Neck Pain

Summary: the study aims to compare the effectiveness of soft tissue, joint mobilization, and tele-rehabilitation within the scope of manual therapy to the exercise program.

60 subjects with cervical degenerative disease will be included in the study after a voluntary consent form is filled out. subjects will randomly be divided into 3 groups according to the order. group 1:home exercise program: after a general education is given to the patients, an exercise program will be taught. patients will be asked to do home exercises for 30-45 minutes once a day, 5 days a week for 8 weeks, and fill in follow-up charts. in addition, reminder messages will be sent to these patients once a week by the physiotherapist. group 2: manual therapy group: after a general education is given to the patients, the same exercise program will be taught. soft tissue and joint mobilizations will be applied to the patients in this group within the scope of manual therapy (mt). mobilizations of the cervical vertebrae, scapula, and thoracic vertebrae will be included. mt will be applied to the patients 2 days a week for 8 weeks. group 3: tele-rehabilitation group: after general education, treatment will be given in the zoom environment. during the 8 weeks, regularly planned exercises will be done via zoom for 30-45 minutes 2 days a week, accompanied by a physiotherapist. patients will apply active cervical and thoracic region mobilizations called self-mobilization. patients will be taught active mobilization applications with the help of a towel for the cervical region, mobilization of the thoracic region with a foam roller. patients will apply those self-mobilization at home in front of the physiotherapist in a visual environment. patients in this group will regularly do the same home exercises on the other days without tele-rehabilitation. measurement and evaluation will be done four times, as pre-treatment, post-treatment (8th week), first follow-up (12 weeks), second follow-up (6th month).

Eligibility criteria:
inclusion criteria: * between the ages of 40-65 * patients diagnosed with cervical degenerative disease * patients with neck pain who have had pain for at least three months * patients who can participate in the treatment program by following whatsapp messages with tele-rehabilitation. exclusion criteria: * patients with an indication for surgery for the cervical region and or a previous history of cervical surgery, * currently receiving treatment from another region, * having severe neurological loss, * having a primary or spinal metastatic malignancy, * having a vascular problem in the upper extremity, * to be diagnosed with advanced osteoporosis, * being pregnant, * diagnosis of diabetes mellitus, * having an inflammatory disease (such as rheumatoid arthritis), * having a history of trauma, * those who have received physical therapy and rehabilitation for the cervical region in the last 6 months will not be included.

Keywords: pain anxiety quality of life neck disability
burdock and blood pressure in african-american women

Conditions: Hypertension

Summary: this is a study of women aged 18-65, to determine the physiological effects of consuming burdock root in supplement form. burdock has long been used by herbalists for its diuretic and blood sugar lowering properties.

this study will allow us to determine the effect of burdock consumption on basic laboratory tests such as the complete metabolic panel (cmp) as well as the effect on blood pressure over time. participants will self-monitor their blood pressures and undergo lab testing. they will also complete symptom inventories to determine subjective factors that change with burdock consumption, such as menstrual water retention. subjects will undergo electronic body composition testing before and after the intervention.

Eligibility criteria:
inclusion criteria: * must be able to swallow tablets * african-american race * able to travel to our clinic in santa monica exclusion criteria: * severely low blood pressure * hypoglycemia * baseline creatinine over 1.2
the influence of prn dry eye omega-3 nutritional regimen on tear osmolarity in cases of dry eye disease

Conditions: Dry Eye Disease

Summary: the investigators hypothesize that oral omega-3-acid triglyceride form will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (tearosmolarity, schirmer-1 test values, corneal staining, and fluorescein tear break-up time) when compared to administration of placebo.


Eligibility criteria:
inclusion criteria: * age ≥18 and ≤ 90 at the time of informed consent * subjects experiencing dry eye based on a global clinical assessment by the attending clinician, subject complaint of dry eye symptoms * presence or history of tear osmolarity (appendix 2) equal to or greater than 312 mosm/l in at least one eye * presence or history of meibomian gland dysfunction (grade 1 or 2) in at least one eye exclusion criteria: * allergy to fish oil or safflower oil * clinically significant eyelid deformity or eyelid movement disorder that is caused by conditions such as notch deformity, incomplete lid closure, entropion, ectropion, hordeola or chalazia * previous ocular disease leaving sequelae or requiring current topical eye therapy other than for ded, including, but not limited to: active corneal or conjunctival infection of the eye and ocular surface scarring active ocular or nasal allergy * lasik or prk surgery that was performed within one year of the screening visit or at any time during the study * ophthalmologic drop use within 2 hours of any study visits. any otc habitual artificial tear should be continued at the same frequency and no change in drop brand * contact lens wear within 12 hours of any study visits * pregnancy or lactation during the study * abnormal nasolacrimal drainage (by history) * punctal cauterization or punctal plug placement within 60 days of screening * prohibited medications - cyclosporine (restasis®); any topical prescription medications (i.e., steroids, nsaids, etc); glaucoma medications; oral tetracyclines or topical macrolides; oral nutraceuticals (flax, black currant seed oils, etc...) within 3 weeks (21 days) of screening and at any time during the study
task-oriented progressive resistance strength training and balance exercises on lower limb in individuals with stroke

Conditions: Stroke

Summary: stroke is ranked as the number fifth cause of death and a main cause of disability in the united states. it affects the arteries which supply blood to and within the brain. if the blood supply to the brain is disrupted, it will not be able to receive oxygen and the nutrients which are transported by those arteries. this leads to the death of brain cells having a magnificent effect on the function of that part.

this study was quasi-experimental trial, to compare the effectiveness of progressive resistive strength exercises and balance exercises in subjects with stroke. subjects with stroke meeting the predetermined inclusion \& exclusion criteria were divided into two groups using lottery method. pre assessment was done using berg balance scale, fugl meyer assessment - lower extremity and step test. subjects in one group were treated with progressive resistive strength training and other group was treated with balance training. each subject received 12 treatment sessions, with 03 treatment sessions per week. results were recorded at the end of 3rd, 6th, 9th and 12th treatment sessions. recorded values were analysed using spss.

Eligibility criteria:
inclusion criteria: * hemiparetic from a single stroke occurring at least a year earlier, not presently receiving any rehabilitation services, * participants should not be receiving any rehabilitation services * participants should be able to walk 10 m independently without an assistive device * participants should be medically stable enough to allow participation, and able to understand instructions and follow commands. exclusion criteria: * participants with any medical condition that would prevent participation in the training program * participants with any uncontrolled health condition for which exercise is contraindicated. * participants with any tumor or neurological signs.

Keywords: balance progressive resistance strength training
helicobacter pylori prevalence in southern region of romania

Conditions: Infections, Helicobacter

Summary: observational study, voluntary participation, 12 months, studying helicobacter pylori prevalence.

observational study, voluntary participation, 12 months, studying helicobacter pylori prevalence. the aim of the study is to evaluate the prevalence of h. pylori infection in several areas of the southern regions of romania, considered as vulnerable pertaining to the access of health services. fecal helicobacter pylori will be tested, together with antibiotic susceptibility.

Eligibility criteria:
inclusion criteria: * adult voluntary participants to "medical services caravan" project by medcorp association exclusion criteria: * age \< 18 years old * no informed consent
daptomycin as an adjuvant agent in the treatment of enterococcal native valve endocarditis.

Conditions: Endocarditis, Bacterial

Summary: the aim of this study is to determine the safety and efficacy of daptomycin when used as an adjuvant agent to standard care in the treatment of proven native valve enterococcal endocarditis. patients with this disease will be offered the option of receiving daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving. the hypothesis of this study is that daptomycin added to standard therapy for enterococcal endocarditis is safe and efficacious. patients who receive daptomycin + standard therapy will be compared to patients who receive standard therapy alone with respect to the following outcomes: 1. safety. 1. the frequency of any grade 3 or 4 toxicity (daids scale) will be measured. 2. the frequency of muscle toxicity or renal toxicity, as determined by predefined criteria. 2. efficacy. 1. clinical efficacy. * time to clearance of bacteremia * cure at 6 weeks following completion of antibiotic therapy * mortality at 6 weeks following completion of antibiotic therapy 2. microbiologic efficacy. * peak and trough serum bactericidal titers * the minimum bactericidal concentration of enterococci to daptomycin we expect to enroll 40 patients over 2 years.


Eligibility criteria:
inclusion criteria: * age 18 or over * definite enterococcal endocarditis, as defined by modified duke criteria * able to complete follow-up 3 and 6 weeks following completion of intravenous antibiotic therapy exclusion criteria: * pregnancy or breast feeding * creatine phosphokinase levels over two times the upper limit of normal * renal insufficiency or dialysis requirement. * presence of chronic indwelling bloodstream catheters or foreign body devices suspected as primary or secondary sites of enterococcal infection unamenable to removal or replacement * inability to discontinue or abstain from use of a hmg coa reductase inhibitor during the study period. * hypersensitivity to any of the study medications. * any condition that, in the investigator's opinion, may interfere with protocol compliance including, but not limited to, active substance abuse and/or dementia. * prosthetic valve endocarditis

Keywords: enterococcus daptomycin endocarditis
study to evaluate the efficacy of labcat tcjuss in patients with depressive episode

Conditions: Depression

Summary: evaluate the therapeutic effects of escitalopram versus an association of escitalopram + trichilia catigua dry extract (labcat tcjuss) in the average alteration on depression score measured by the hamilton scale (ham-d).

evaluate the therapeutic effects of escitalopram versus an association of escitalopram + labcat tcjuss in the following aspects: 1. alteration on the average score of anhedonia symptoms through the shaps-c scale; 2. alteration of average scores of global clinical impression carried out by the investigator (cgi-s e cgi-i); 3. average scores of the patient global evaluation

Eligibility criteria:
inclusion criteria: * subjects from both sexes aged between 18 and 65 years; * patient diagnosed with mild depression episode confirmed by psychiatric and psychometric evaluation, presenting basal scores above 08 and below 24 measured by the hamilton rating scale (ham-d); * capable of understanding the nature and objective of the study, including risks and adverse effects and intended to cooperate with the researcher and act in accordance with the requirements of the entire protocol, which comes to be confirmed by signing the informed consent. exclusion criteria: * have a known hypersensitivity to trichilia catigua or history of serious adverse reactions; * shows risk of suicide, assault, murder or moral exposure; * clinical history of bleeding disorders; * drug addiction, including alcohol; * known or suspected neoplasia; * knowledge positive test result for the human immunodeficiency virus; * patient not willing to adhere to the procedures of the protocol; * for women, can not be pregnant or nursing and must be in use of a contraception method during the participation in the study; * patients using other drugs with sedative or antidepressant action, which can not be suspended for 15 days (wash out); * diabetics; * hyperthyroidism; * participation in any experimental study or use of any experimental drug three months before the start of this study; * has any condition which the investigator deems relevant to the non-participation of the study.
a single center, randomized, open label, parallel group, phase 3 study to evaluate the efficacy of dapagliflozin in subjects with nonalcoholic fatty liver disease

Conditions: Fatty Liver

Summary: this trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with nonalcoholic fatty liver disease. this is a principal investigator initiate study. this study is supported by liver disease prevention \& treatment research foundation. dapagliflozin will be provided free of charge by astrazeneca.


Eligibility criteria:
inclusion criteria for inclusion in the study patients should fulfil the following criteria: 1. provision of informed consent prior to the time of registration. 2. aged 20-74 years male or female who are diagnosed with nafld and fibroscan shows cap score ≥ 252 db/m (≥steatosis grade 2). 3.30 or more ml/min/1.73 m2 of estimated glomerular filtration rate 4.female subjects must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study (from the time they sign consent) and for 1 month after the last dose of ip to prevent pregnancy. in addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used. 5.subjects who are blood donors should not donate blood during the study and for 1 month following their last dose of ip. exclusion criteria subjects should not enter the study if any of the following exclusion criteria are fulfilled: 1. viral hepatitis or other types of liver disorder (e.g. drug-induced or autoimmune hepatitis). 2. alcohol consumption above recommended limits (male: more than 30g/ day; female: more than 20g/day converting to ethanol). 3. serious liver dysfunction (child-pugh b or c). 4. history of any other malignancy within 1 years (with the exception of successfully treated non-melanoma skin cancers). 5. patients with a known hypersensitivity to investigator product (ip). 6. participation in another clinical trial within the previous 30 days or involvement in the planning and/or conduct of the study. 7. previous enrolment or randomisation in the present study. 8. active gallbladder diseases 9. for women is currently pregnant (confirmed with positive pregnancy test) or breast feeding.
testing content delivery models for momconnect

Conditions: Immunization Coverage; Breastfeeding; Hematological Diseases

Summary: the case for mobile health (mhealth) has been gaining traction as a source to improve health outcomes of individuals. mhealth refers to the use of information and communication technologies (ict) to support health care. the ubiquity and penetration of mobile phones presents the opportunity to deliver health care services directly to citizens, with the greatest potential gains in under-resourced health ecosystems. operating for 8 years and currently supporting 1.28 million mothers through their pregnancies and early childhood care, momconnect represents one of the largest maternal health messaging platforms in the world. implemented at the national level, momconnect has been credited with being the first national-scale mhealth program of its kind and has won numerous international awards. as a whatsapp-delivered service, momconnect has been limited by whatsapp's historical terms of service. in its current form, momconnect can only start a conversation with mothers once a week by alerting them of their upcoming antenatal care (anc) appointment. recent changes to whatsapp's terms of service have removed the restriction around push messages for certain programs, including momconnect. messages have historically been restricted to weekly conversation starters and carry only generic administrative reminder-style information. as a result, it is possible that many mothers are failing to engage with the content as much as they could. if mothers were more engaged, it could greatly increase exposure and knowledge of reducing the total number of mothers exposed to critical maternal and infant health content. with the updated terms of service, there is an opportunity to test different ways of engaging mothers. this study proposes to evaluate, through a randomized controlled trial (rct), the relative effect of three new behaviorally-informed program models on key knowledge of and adoption of healthy behaviors.


Eligibility criteria:
inclusion criteria: * pregnant women above the age of 18 signing up for momconnect when being between 16-30 weeks pregnant exclusion criteria: * all others
impact of human papillomavirus (hpv) vaccination on burden of disease in patients with actinic keratosis

Conditions: Actinic Keratoses; Basal Cell Carcinoma; Squamous Cell Carcinoma

Summary: a double-blind, randomized, placebo controlled intervention trial on patients with actinic keratosis.

endeavoring to develop a new therapeutic and preventative strategy for patients with ak, this study aims to investigate the impact of 9-valent hpv vaccination on ak burden and -development over the course of 12 months. seventy actinic keratosis (ak) patients are randomized 1:1 to two parallel groups that receive blinded hpv vaccination or sham placebo (isotonic nacl) vaccination at baseline (day 0), month 2 and month 6. at month 6 and 9, both groups undergo lesion-directed cryotherapy of olsen grade ii-iii aks. treatment response, based on percentage change (%) in baseline number of ak lesions in a predefined test area (primary outcome), is evaluated at months 2, 6, 9, and 12.

Eligibility criteria:
inclusion criteria: subjects who meet all the following criteria are eligible to participate in this study: 1. high ak burden, defined as ≥15 ak lesions in the included test area (50-100 cm2) at baseline 2. test area does not involve the ala nasi, eyelids, nasolabial folds, or periauricular skin 3. \>18 years of age at baseline 4. fitzpatrick skin phototype i-iv 5. legally competent, able to give verbal and written informed consent 6. subject is willing to participate and can comply with protocol requirements including the refraining from other therapy (with the exception of kc treatment) in the test area for the duration of the trial. 7. women of childbearing potential1 must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment and be on effective contraception2 until discontinuation of the vaccine therapy. additional pregnancy testing will not be conducted unless pregnancy is suspected. 1female subjects are considered of childbearing potential unless they have been hysterectomized or have undergone tubal ligation or have been post-menopausal for at least one year prior to first visit. 2intrauterine device or hormonal contraception (oral, implant, patch, vaginal ring, injection). exclusion criteria: subjects meeting any of the following criteria are not eligible to participate in this study: 1. known or suspected immunosuppression (by disease or immunosuppressive drug) 2. history of vaccine-related allergic reactions or known allergy to gardasil®9 ingredients or yeast 3. previously vaccinated with any hpv vaccine 4. history of keloids 5. other skin diseases present in the test area at baseline 6. lactating or pregnant women
effectiveness of a curcumin mouthwash in preventing traumatic ulcers in patients with fixed orthodontic appliances

Conditions: Oral Ulcer; Orthodontic Appliances, Fixed

Summary: the study is a randomized controlled trial. the participants will be equally allocated into 2 groups to compare clinical effectiveness of curcumin mouthwash in fixed orthodontic patients during the first month of treatment.

patients who require fixed orthodontic appliances as part of their orthodontic treatment at the faculty of dentistry, chulalongkorn university will be asked if they will volunteer for this clinical research. participants will be informed about the objectives of the study, study process, advantages, disadvantages before making a decision to participate in this study. the consent form will be signed prior to participating in the study. a week before bracket cementation visit, a participant will attend his/her appointment for a full clinical history taking and oral screening exam by one examiner. each participant will be allocated by a trial number and receive 3 bottles of either placebo or curcumin mouthwash accordingly. a tube of sodium lauryl sulfate (sls)-free, non-herbal toothpaste and 1 toothbrush will be provided to each participant. moreover, the instruction vdo will be given to participants to "rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing" in the first 28 days after bracket cementation. then, participants will be provided with a daily record form on google form and requested to record every day during the trial.

Eligibility criteria:
inclusion criteria: * fixed orthodontic patients aged 12-30 years old * fixed orthodontic appliances on at least 1 arch (at least 10 teeth per arch) * patients with good general health without any systemic diseases * patients who are not using any herbal toothpaste or any mouthwash in daily life for the past 2 weeks * patients who are not taking any medications which may influenced the pattern of oral ulceration * patients who are willing and able to cooperate with all aspects of the protocol and able to communicate effectively and give informed written consent from parents if patients are younger than 18 years old exclusion criteria: * cigarette smoking * history of hypersensitivity or allergy to turmeric or other ingredients of mouthwash * history of oral mucosal lesions and skin diseases * oral ulceration or inflammation with unknown etiology * pregnant or lactating women

Keywords: curcumin curcumin mouthwash traumatic ulcers fixed orthodontic appliances